- call +1-201-465-4211
- email sales@mrinsights.biz
Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
Scope of the Report:
This report studies the Nonalcoholic Steatohepatitis (NASH) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Nonalcoholic Steatohepatitis (NASH) market by product type and applications/end industries.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
At present, vitamin E & pioglitazone segment dominates the non-alcoholic steatohepatitis (NASH) market, due to efficacy.
Asia-Pacific presents lucrative opportunities for the key players operating in the non-alcoholic steatohepatitis (NASH) market. Some factors such as growth in diagnostic techniques, rapid rise in prevalence NASH, growth in economies, and increase in demand for NASH therapeutics drive the market growth in Asia-Pacific.
The global Nonalcoholic Steatohepatitis (NASH) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Nonalcoholic Steatohepatitis (NASH).
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Tobira Therapeutics
Cadila Healthcare
Conatus Pharmaceuticals
Galmed Pharmaceuticals
Gemphire Therapeutics
Genfit
Gilead Sciences
Intercept Pharmaceuticals
Novartis International
Shire
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Vitamin E & Pioglitazone
Ocaliva
Elafibranor
Selonsertib & Cenicriviroc
Market Segment by Applications, can be divided into
Hospital Pharmacy
Online Provider
Retail Pharmacy
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Nonalcoholic Steatohepatitis (NASH) Market Overview
1.1 Product Overview and Scope of Nonalcoholic Steatohepatitis (NASH)
1.2 Classification of Nonalcoholic Steatohepatitis (NASH) by Types
1.2.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue Comparison by Types (2017-2023)
1.2.2 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Types in 2017
1.2.3 Vitamin E & Pioglitazone
1.2.4 Ocaliva
1.2.5 Elafibranor
1.2.6 Selonsertib & Cenicriviroc
1.3 Global Nonalcoholic Steatohepatitis (NASH) Market by Application
1.3.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Global Nonalcoholic Steatohepatitis (NASH) Market by Regions
1.4.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Nonalcoholic Steatohepatitis (NASH) Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Nonalcoholic Steatohepatitis (NASH) Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Nonalcoholic Steatohepatitis (NASH) Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Nonalcoholic Steatohepatitis (NASH) Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Nonalcoholic Steatohepatitis (NASH) Status and Prospect (2013-2023)
1.5 Global Market Size of Nonalcoholic Steatohepatitis (NASH) (2013-2023)
2 Manufacturers Profiles
2.1 Tobira Therapeutics
2.1.1 Business Overview
2.1.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Tobira Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.2 Cadila Healthcare
2.2.1 Business Overview
2.2.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Cadila Healthcare Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.3 Conatus Pharmaceuticals
2.3.1 Business Overview
2.3.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Conatus Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.4 Galmed Pharmaceuticals
2.4.1 Business Overview
2.4.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.5 Gemphire Therapeutics
2.5.1 Business Overview
2.5.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Gemphire Therapeutics Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.6 Genfit
2.6.1 Business Overview
2.6.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Genfit Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.7 Gilead Sciences
2.7.1 Business Overview
2.7.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Gilead Sciences Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.8 Intercept Pharmaceuticals
2.8.1 Business Overview
2.8.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Intercept Pharmaceuticals Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.9 Novartis International
2.9.1 Business Overview
2.9.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Novartis International Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
2.10 Shire
2.10.1 Business Overview
2.10.2 Nonalcoholic Steatohepatitis (NASH) Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Shire Nonalcoholic Steatohepatitis (NASH) Revenue, Gross Margin and Market Share (2016-2017)
3 Global Nonalcoholic Steatohepatitis (NASH) Market Competition, by Players
3.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Nonalcoholic Steatohepatitis (NASH) Players Market Share
3.2.2 Top 10 Nonalcoholic Steatohepatitis (NASH) Players Market Share
3.3 Market Competition Trend
4 Global Nonalcoholic Steatohepatitis (NASH) Market Size by Regions
4.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue and Market Share by Regions
4.2 North America Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
4.3 Europe Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
4.5 South America Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
5 North America Nonalcoholic Steatohepatitis (NASH) Revenue by Countries
5.1 North America Nonalcoholic Steatohepatitis (NASH) Revenue by Countries (2013-2018)
5.2 USA Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
5.3 Canada Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
5.4 Mexico Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
6 Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Countries
6.1 Europe Nonalcoholic Steatohepatitis (NASH) Revenue by Countries (2013-2018)
6.2 Germany Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
6.3 UK Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
6.4 France Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
6.5 Russia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
6.6 Italy Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Countries
7.1 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue by Countries (2013-2018)
7.2 China Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
7.3 Japan Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
7.4 Korea Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
7.5 India Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
8 South America Nonalcoholic Steatohepatitis (NASH) Revenue by Countries
8.1 South America Nonalcoholic Steatohepatitis (NASH) Revenue by Countries (2013-2018)
8.2 Brazil Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
8.3 Argentina Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
8.4 Colombia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Nonalcoholic Steatohepatitis (NASH) by Countries
9.1 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Revenue by Countries (2013-2018)
9.2 Saudi Arabia Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
9.3 UAE Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
9.4 Egypt Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
9.5 Nigeria Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
9.6 South Africa Nonalcoholic Steatohepatitis (NASH) Revenue and Growth Rate (2013-2018)
10 Global Nonalcoholic Steatohepatitis (NASH) Market Segment by Type
10.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue and Market Share by Type (2013-2018)
10.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Type (2018-2023)
10.3 Vitamin E & Pioglitazone Revenue Growth Rate (2013-2023)
10.4 Ocaliva Revenue Growth Rate (2013-2023)
10.5 Elafibranor Revenue Growth Rate (2013-2023)
10.6 Selonsertib & Cenicriviroc Revenue Growth Rate (2013-2023)
11 Global Nonalcoholic Steatohepatitis (NASH) Market Segment by Application
11.1 Global Nonalcoholic Steatohepatitis (NASH) Revenue Market Share by Application (2013-2018)
11.2 Nonalcoholic Steatohepatitis (NASH) Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacy Revenue Growth (2013-2018)
11.4 Online Provider Revenue Growth (2013-2018)
11.5 Retail Pharmacy Revenue Growth (2013-2018)
12 Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast (2018-2023)
12.1 Global Nonalcoholic Steatohepatitis (NASH) Market Size Forecast (2018-2023)
12.2 Global Nonalcoholic Steatohepatitis (NASH) Market Forecast by Regions (2018-2023)
12.3 North America Nonalcoholic Steatohepatitis (NASH) Revenue Market Forecast (2018-2023)
12.4 Europe Nonalcoholic Steatohepatitis (NASH) Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Nonalcoholic Steatohepatitis (NASH) Revenue Market Forecast (2018-2023)
12.6 South America Nonalcoholic Steatohepatitis (NASH) Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Nonalcoholic Steatohepatitis (NASH) Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Nonalcoholic Steatohepatitis (NASH) Picture
Table Product Specifications of Nonalcoholic Steatohepatitis (NASH)
Table Global Nonalcoholic Steatohepatitis (NASH) and
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
